Heron Therapeutics, Inc.has announced that the FDA has approved Cinvanti (aprepitant) injectable emulsion, for intravenous infusion. Cinvanti is a substance...
Heron Therapeutics announced that the FDA has approved Heron's supplemental New Drug Application (sNDA) for Cinvanti (aprepitant) injectable emulsion for...
FDA approves expanded indication for Cinvanti in nausea and vomiting
Heron Therapeutics announced the initiation of the GUARDS-1 Study, a Phase II clinical study evaluating Cinvanti (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19).